Shaman Pharmaceuticals, Inc.

Joseph L Evans

Steven Row King

Diana M Fort

Wayne D Inman

Christopher D Mendez

Jolad D Shivanand

Rosa P Ubillas

Novel hypoglycemically active eremophilanolide sesquiterpenes which can be isolated from Psacalium spp., processes for obtaining the novel eremophilanolide sesquiterpenes and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes are described. Further described is the use of epicacalone, cacalone, cacalol or dimaturin as hypoglycemic agents, for example, in the treatment of diabetes. In a preferred embodiment, the hypoglycemically active compounds are obtained from the roots of Psacalium decompositum. As agents for the treatment of diabetes, the hypoglycemically active compounds of the present inventions are useful for treating insulin-dependent (type I) and/or non-insulin-dependent (type II) diabetes.

Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of

Novel terpenoid-type quinones which can be obtained from Pycnanthus spp., processes for obtaining the novel terpenoid-type quinones and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes are described. In a preferred embodiment, the novel terpenoid-type quinones are obtained from the leaves and stems of Pycnanthus angolensis. As agents for the treatment of diabetes, the novel terpenoid quinones are useful for treating insulin-dependent (type I) and/or non-insulin-dependent (type II) diabetes.

Terpenoid-type quinones for treatment of diabetes

Growing community of inventors

San Francisco, CA, United States of America

Joseph L Evans